van der Willigen A H, Wagenvoort J H, Schalla W O, Knapp J S, Boot J M, Heeres-Weststrate P L, Michel M F, van Klingeren B, Stolz E
Department of Dermato-Venerology, University Hospital Rotterdam-Dijkzigt, The Netherlands.
Antimicrob Agents Chemother. 1988 Apr;32(4):426-9. doi: 10.1128/AAC.32.4.426.
Uncomplicated urogenital and concomitant oropharyngeal gonorrhea in 424 male and female patients was treated in a randomized comparative study with 0.5 g of cefodizime (89 men and 54 women), 1 g of cefodizime (87 men and 52 women), or 1 g of cefotaxime (86 men and 56 women). The cure rates were 100% for men and women in the group given 0.5 g of cefodizime, 100% for men and women in the group given 1 g of cefodizime, and 99% for men and 100% for women in the group given 1 g of cefotaxime. The MICs of cefodizime and cefotaxime for the isolate of Neisseria gonorrhoeae ranged from 0.004 to 0.06 micrograms/ml. Chlamydia trachomatis was isolated before treatment in 15% and after treatment in 13% of all patients. Side effects, such as nausea, diarrhea, abdominal pain, genital candidiasis, and pain at the site of injection, developed in 4% of the patients given cefodizime. Side effects, such as vertigo, genital candidiasis, fatigability, and diarrhea, developed in 4% of the patients treated with cefotaxime. In both groups of patients, the side effects were mild and transient. Cefodizime and cefotaxime are safe and effective agents in the treatment of uncomplicated urogenital gonorrhea.
在一项随机对照研究中，对424例患有单纯性泌尿生殖系统淋病以及合并口咽淋病的男性和女性患者进行了治疗，分别给予0.5g头孢地嗪（89名男性和54名女性）、1g头孢地嗪（87名男性和52名女性）或1g头孢噻肟（86名男性和56名女性）。给予0.5g头孢地嗪组的男性和女性治愈率均为100%，给予1g头孢地嗪组的男性和女性治愈率均为100%，给予1g头孢噻肟组的男性治愈率为99%，女性治愈率为100%。头孢地嗪和头孢噻肟对淋病奈瑟菌分离株的最低抑菌浓度范围为0.004至0.06微克/毫升。所有患者中，15%在治疗前分离出沙眼衣原体，13%在治疗后分离出沙眼衣原体。给予头孢地嗪的患者中有4%出现副作用，如恶心、腹泻、腹痛、生殖器念珠菌病和注射部位疼痛。接受头孢噻肟治疗的患者中有4%出现副作用，如眩晕、生殖器念珠菌病、疲劳和腹泻。两组患者的副作用均轻微且短暂。头孢地嗪和头孢噻肟是治疗单纯性泌尿生殖系统淋病的安全有效药物。
